CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
‘Everybody’s scared to death of Trump’: Even some Ron DeSantis supporters in South Carolina think he’s going to lose Read more